Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–
Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor …
Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor …
Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction
Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …
Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial
Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …
Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF
Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …
chronic kidney disease that complicates pharmacological management and is associated …
Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and …
ME Nassif, SL Windsor, K Gosch… - Circulation: Heart …, 2023 - Am Heart Assoc
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the …
M Vaduganathan, BL Claggett, P Jhund… - JAMA …, 2022 - jamanetwork.com
Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …
Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the dapagliflozin and prevention of …
Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …
Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial
SD Solomon, M Vaduganathan, BL Claggett… - Heart Failure, 2022 - jacc.org
Objectives This report describes the baseline clinical profiles and management of DELIVER
(Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction …
(Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction …
Dapagliflozin for heart failure with preserved ejection fraction: will the DELIVER study deliver?
DM Williams, M Evans - Diabetes Therapy, 2020 - Springer
Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are
often limited to diuretics to improve symptoms as no therapies demonstrate a mortality …
often limited to diuretics to improve symptoms as no therapies demonstrate a mortality …
相关搜索
- ejection fraction heart failure
- dapa hf heart failure
- effect of dapagliflozin heart failure
- dapa hf ejection fraction
- clinical benefit heart failure
- effect of dapagliflozin cardiovascular death
- dapa hf patient level
- patient level heart failure
- cardiovascular death heart failure
- dapa hf efficacy of dapagliflozin
- effect of dapagliflozin diabetes mellitus
- diabetes mellitus heart failure
- ejection fraction dapagliflozin effects
- clinical benefit dapagliflozin in patients
- functional status dapagliflozin effects
- efficacy of dapagliflozin outcomes in patients